The aims of future research should include HK1 studies involving other PAH animal models, as well as in vivo and in vitro studies of related biochemical pathways to evaluate whether HK1 inhibitors can reduce mPAP, RVSP, RVHI and ameliorate PAH. This evidence concerns the gene HK1 and pulmonary arterial hypertension.